Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Lunella Biotech Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners and 4 distinct art units. This distribution means that every pending matter is currently being reviewed by a different examiner in a different unit, which prevents the concentration of the company's pending workload under any single individual. The presence of 4 distinct art units indicates that the company's current patent applications cover a variety of technical sub-sectors within the biotechnology field.
JEAN-LOUIS, SAMIRA JM is the busiest examiner for the portfolio. This examiner is currently managing 1 pending office action for the company, indicating that the pending workload is divided equally among several examiners. Because the 4 pending office actions are spread across 4 distinct examiners, the applicant must navigate four different examination styles and unit-specific requirements. This decentralized approach to prosecution can lead to varying timelines for the resolution of each matter, as each of the 4 distinct art units may have different average response times and examination trends.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JEAN-LOUIS, SAMIRA JM | 1 | 60.9% | +45.4% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| BARHAM, BETHANY P | 1 | 51.8% | +32.2% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924614 | MYRISTOYL DERIVATIVES OF 9-AMINO-DOXYCYCLINE FOR TARGETING CANCER STEM CELLS AND PREVENTING METASTASIS | BARHAM, BETHANY P | — |
| 17414842 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | WAX, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | VALENROD, YEVGENY | 10d overdue |
| 18722474 | MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS | JEAN-LOUIS, SAMIRA JM | — |
| 17924614 | MYRISTOYL DERIVATIVES OF 9-AMINO-DOXYCYCLINE FOR TARGETING CANCER STEM CELLS AND PREVENTING METASTASIS | BARHAM, BETHANY P | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1693 | 1 |
| 1628 | 1 |
| 1611 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722474 | MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS | JEAN-LOUIS, SAMIRA JM | 1642 | §112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18425427 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | OLSON, ANDREA STEFFEL | 1693 | §103Other | Non-Final OA | 34d | Pending | Jan 29, 2024 |
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | VALENROD, YEVGENY | 1628 | §112 | Final Rejection | 10d overdue | Pending | Dec 15, 2023 |
| 17924614 | MYRISTOYL DERIVATIVES OF 9-AMINO-DOXYCYCLINE FOR TARGETING CANCER STEM CELLS AND PREVENTING METASTASIS | BARHAM, BETHANY P | 1611 | §102§103Other | Final Rejection | — | Pending | Nov 10, 2022 |
| 17414842 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Jun 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLunella Biotech Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Samira Jm Jean-Louis has the most, with 1 of Lunella Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
